The purpose of this study is to determine whether the addition of meropenem to colistin is better than colistin alone in the treatment of clinically significant infections caused by multi-drug resistant bacteria
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
406
Atikkon Hospital
Athens, Greece
Laikon Hosptial
Athens, Greece
Rambam Health Care Center
Haifa, Israel
Rabin Medical Center
Petach-Tikvah, Israel
Clinical success
defined as a composite of all of the following, all measured at 14 days: * Patient alive * Systolic blood pressure \>90 mmHg without need for vasopressor support * Stable or improved SOFA score, define as: * for baseline SOFA ≥ 3: a decrease of at least 30%; * for baseline SOFA \<3: stable or decreased SOFA score * For patients with HAP/ VAP, PaO2/FiO2 ratio stable or improved * For patients with bacteremia, no growth of the initial isolate in blood cultures taken on day 14 if patient still febrile
Time frame: 14 days
Secondary outcomes and adverse events
14 and 28-day all-cause mortality. If patients are discharged or death occurs before end of follow-up (day 28), we will end data collection at that date. We will attempt to determine survival status at day 28 for all patients (central registry in Israel; re-admissions, rehabilitation centers, hospital transfers in Greece and Italy).
Time frame: 14 and 28 days
Clinical success with modification
Clinical success, but with modification to the antibiotic treatment not permitted by protocol
Time frame: 14 days
Time to defervescence
defined as time to reach a temperature of \<38°C with no recurrence for 3 days
Time frame: 28 days
Time to weaning
Time to weaning from mechanical ventilation in VAP for patients weaned alive
Time frame: 28 days
Time to hospital discharge
Time to hospital discharge for patient discharged alive
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Monaldi Hospital, University of Naples S.U.N.
Naples, Italy
Agostino Gemelli Hospital
Rome, Italy
Microbiological failure
Microbiological failure, defined as isolation of the initial isolate (phenotypically identical) in a clinical sample (blood or other) 7 days or more after start of treatment or its identification in respiratory samples. * For all patients with VAP/ HAP sputum or tracheal aspirates will be obtained on day 7, regardless of clinical response * For all patients with UTI, a repeat urine culture will be obtained on day 7, regardless of clinical response * For patients with bacteremia, blood cultures will be repeated on day 7 and 14, only if the patient is febrile at that time
Time frame: 28 days
Superinfections
Defined as a new clinically or microbiologically-documented infections by CDC criteria within 28 days
Time frame: 28 days
New resistant infection
Colonization or infection by newly-acquired (other species than the initial infection) carbapenem-resistant or colistin-resistant Gram-negative bacteria. Colonization will be assessed by rectal surveillance
Time frame: 28 days
CDAD
Clostridium-difficile-associated diarrhea, defined by diarrhea with a positive C. difficile toxin test
Time frame: 28 days